Research
Hormonal
Pharmacological inhibition of FASN activity may prevent or reverse insulin-related metabolic disorders and reduce cancer risk.
FASN inhibitors are not yet available, but research suggests they could be a valuable future treatment for insulin resistance and cancer. For now, focusing on insulin sensitivity through lifestyle is the best approach.
ModerateConditionalMEDIUM confidence
If we accept the paradigm of FASN dysfunction as a previously unrecognized link between insulin resistance, type 2 diabetes, and cancer, the use of insulin sensitizers in parallel with forthcoming FASN inhibitors should be a valuable therapeutic approach...
Why this rating
Based on animal models and preliminary human genetic data (Val1483Ile polymorphism), but lacks large-scale clinical trial data for FASN inhibitors.
Source
Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer
Javier A. Menéndez et al. · Clinical Chemistry · 2009
DOI 10.1373/clinchem.2008.115352
narrative_reviewCited 181×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin treatment is associated with reduced cancer risk, potentially through AMPK activation and inhibition of mTOR.Good
- Deregulation of fatty acid synthase (FASN)-catalyzed de novo fatty acid biogenesis drives a 'lipogenic state' that links insulin resistance, type 2 diabetes, and cancer.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →